Subscribe
shutterstock_1486264271_jhvephoto
JHVEphoto / Shutterstock.com
30 January 2020AmericasSarah Morgan

Fed Circuit hands win to Galderma in Teva suit

The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Nestlé Skin Health has face injection infringement claims thrown out
17 December 2019   Nestlé Skin Health will not face claims that it misappropriated trade secrets related to a training platform for teaching medical professionals how to perform facial injections, a US court has ruled.
Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Big Pharma
US appeals court upholds decision on wrinkle treatment
29 June 2023   Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Nestlé Skin Health has face injection infringement claims thrown out
17 December 2019   Nestlé Skin Health will not face claims that it misappropriated trade secrets related to a training platform for teaching medical professionals how to perform facial injections, a US court has ruled.
Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Big Pharma
US appeals court upholds decision on wrinkle treatment
29 June 2023   Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.

More on this story

Americas
Nestlé Skin Health has face injection infringement claims thrown out
17 December 2019   Nestlé Skin Health will not face claims that it misappropriated trade secrets related to a training platform for teaching medical professionals how to perform facial injections, a US court has ruled.
Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Big Pharma
US appeals court upholds decision on wrinkle treatment
29 June 2023   Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?